FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay 

The FDA has de­nied Astel­las’ at­tempt to bol­ster the la­bel for its vi­sion loss treat­ment Iz­er­vay with ad­di­tion­al two-year da­ta.

Iz­er­vay, the cen­ter­piece of Astel­las …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER